Arca
Skip to content
Tools
Tools

Arthritis

Drug research and approvals for arthritis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 1,059 studies of arthritis are recruiting on ClinicalTrials.gov, Health Canada has authorized 123 drug trials for it since 2013, FDA has 11 approved and 15 open orphan designations naming it, and the EU has 51 authorised medicines for it.

  • Recruiting worldwide: 1,059
  • Trials authorized in Canada: 123
  • FDA orphan approvals: 11
  • EU medicines: 51

Recruiting now

Newest posted first, of 1,059 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 13

Phase 3 1

How its trials ended

3,882 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 1,101 whose ending is known, 59% met their primary endpoint, 6% missed it and 35% stopped early.

  • Completed, result not reported1,68543%
  • Met its primary endpoint64817%
  • Ongoing61716%
  • Status unknown47912%
  • Stopped: other or unclear1825%
  • Stopped: enrollment or feasibility862%
  • Missed its primary endpoint692%
  • Stopped: sponsor or business decision672%
  • Stopped: lack of efficacy381%
  • Stopped: funding7<1%
  • Stopped: safety4<1%

Trials authorized in Canada

The 10 newest of 123; search them all in Canada trials
Nov 13, 2026A phase 2a, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of MK-8690 in participants with rheumatoid arthritisMK-8690Merck & Co. (MSD)Pending
Aug 11, 2026A randomized, double-blind, placebo-controlled, multicenter phase 2a/b study assessing the efficacy, safety and tolerability of DDY391 in participants with…DDY391Novartis PharmaceuticalsPending
May 13, 2026A phase 3, multicenter, long-term extension study to evaluate the long-term safety, tolerability, and efficacy of zasocitinib (TAK-279) in subjects with active…Zasocitinib (TAK-279)Takeda Pharmaceuticals USAPending
Apr 13, 2026A phase 2b, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of tulisokibart in participants with psoriatic arthritisTulisokibart (MK-7240)Merck & Co. (MSD)Ongoing
Nov 7, 2025A multicentre, parallel-group, phase II, randomised, double-blind, 4 arm study to evaluate efficacy and safety of AZD1163 in participants with moderately-to…AZD1163AstraZeneca PharmaceuticalsOngoing
Aug 22, 2025A phase 2b, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of tulisokibart in participants with rheumatoid arthritisTulisokibart (MK-7240)Merck & Co. (MSD)Ongoing
Aug 19, 2025A phase 2, multicenter, platform study of targeted therapies for the treatment of adult subjects with moderately to severely active rheumatoid arthritisLutikizumab (ABT-981) / Ravagalimab (ABBV-323)AbbVieOngoing
Apr 11, 2025A phase 2 multicenter, randomized, platform study of targeted therapies for the treatment of adult subjects with active psoriatic arthritisLutikizumab (ABT-981) / Risankizumab (ABBV-066)AbbVieOngoing
Mar 5, 2025A multi-center, randomized, double-blind, and placebo-controlled phase 3 study to evaluate the efficacy and safety of zasocitinib (TAK-279) in subjects with…Zasocitinib (TAK-279)Takeda Pharmaceuticals USAOngoing
Feb 7, 2025A phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of JNJ-77242113 for the treatment of…Icotrokinra (JNJ-77242113)Johnson & JohnsonOngoing

FDA orphan designations

Approved first, then open designations, newest first; 15 of 26
Apr 26, 2024RinvoqTreatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response…AbbVie, Inc.Approved
Sep 29, 2020Simponi Aria®Treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and olderJanssen Research & Development, LLCApproved
Jun 16, 2020CanakinumabILARIS is indicated for the treatment of active Still’s disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile…Novartis Pharmaceuticals CorporationApproved
May 11, 2018ActemraACTEMRA® (tocilizumab) for subcutaneous injection is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in…Genentech, Inc.Approved
Apr 25, 2017XatmepManagement of pediatric patients with active polyarticular juvenile idiopathic arthritis (pJIA) who have had an insufficient therapeutic…Silvergate Pharmaeuticals, Inc.Approved
Sep 30, 2014HumiraReducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and…AbbVie Inc.Approved
May 9, 2013IlarisTreatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older.Novartis Pharmaceuticals CorporationApproved
Apr 29, 2013ActemraACTEMRA® (tocilizumab) for subcutaneous injection is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in…Genentech, Inc.Approved
Feb 21, 2008HumiraReducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and…AbbVie Inc.Approved
Aug 11, 2005MobicFor relief of the signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis in patients 2 years of age or…Avondale PharmaceuticalsApproved
May 27, 1999EnbrelReducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and olderImmunex CorporationApproved
Aug 16, 2017UpadacitinibTreatment of pediatric systemic juvenile idiopathic arthritisAbbVie, Inc.Designated
Jul 3, 2017Tadekinig alfaTreatment of Still's disease, including adult-onset Still's disease (AoSD) and systemic juvenile idiopathic arthritis (sJIA)AB2 Bio LtdDesignated
Jan 11, 2017Protoplasmic protein matrix, omega-3 fatty oils, vitamins,…Treatment of juvenile rheumatoid arthritis.Leonard S. Girsh, MDDesignated
Jan 5, 2017Celecoxib oral liquid suspensionTreatment of pediatric juvenile idiopathic arthritisNuBioPharma, LLCDesignated

Medicines authorised in the EU

Newest first; 15 of 51
Nov 12, 2026InijaqTofacitinib · genericGedeon Richter Plc.EMA ↗
Apr 27, 2026TuyoryTocilizumab · biosimilarChemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.)EMA ↗
Apr 23, 2026FubelvEtanercept · biosimilarBiosimilar Collaborations Ireland LimitedEMA ↗
Feb 10, 2026GotenfiaGolimumab · biosimilarStada Arzneimittel AGEMA ↗
Nov 17, 2025GobivazGolimumab · biosimilarAdvanz Pharma LimitedEMA ↗
Feb 14, 2025AvtozmaTocilizumab · biosimilarCelltrion Healthcare Hungary Kft.EMA ↗
Sep 19, 2024ItuxrediRituximab · biosimilarReddy Holding GmbHEMA ↗
Jun 20, 2024Tosmova (previously Tocilizumab STADA and Tofidence)Tocilizumab · biosimilarSTADA Arzneimittel AGEMA ↗
Apr 19, 2024Apremilast AccordApremilast · genericAccord Healthcare S.L.U.EMA ↗
Sep 15, 2023TyenneTocilizumab · biosimilarFresenius Kabi Deutschland GmbHEMA ↗
Mar 24, 2023SotyktuDeucravacitinibBristol-Myers Squibb Pharma EEIGEMA ↗
Nov 15, 2021HukyndraAdalimumab · biosimilarStada Arzneimittel AGEMA ↗
Nov 12, 2021LibmyrisAdalimumab · biosimilarStada Arzneimittel AGEMA ↗
Aug 20, 2021BimzelxBimekizumabUCB Pharma S.A.EMA ↗
Feb 11, 2021YuflymaAdalimumab · biosimilarCelltrion Healthcare Hungary Kft.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.